'Psoriasis 13 3' presentation slideshows

R&I: Psoriasis - Identifying and Commercializing Market

Over the last decade, a greater understanding of the underlying pathophysiology of psoriasis has increased emphasis on developing immuneomodulating therapies, as opposed to largely symptomatic treatments. This is currently reflected in a competitive market dominated by multiple disease-modifying biologic therapies (inhibitors of TNF-a and IL-12/IL-23) and generic small-molecule therapies. Detailed report at: http://www.reportsandintelligence.com/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation-market

266 views • 9 slides